

**Second Regular Session  
Seventy-fifth General Assembly  
STATE OF COLORADO**

**REVISED**

*This Version Includes All Amendments Adopted  
on Second Reading in the Second House*

LLS NO. 26-0863.01 Brita Darling x2241

**HOUSE BILL 26-1336**

---

**HOUSE SPONSORSHIP**

**Lindsay and Winter T.**, Boesenecker, Brown, Clifford, Duran, Goldstein, Gonzalez R., Johnson, Marshall, McCluskie, McCormick, Nguyen, Rydin, Smith, Stewart K.

**SENATE SPONSORSHIP**

**Pelton R. and Cutter,**

---

**House Committees**  
Health & Human Services

**Senate Committees**  
Health & Human Services

---

**A BILL FOR AN ACT**

101 **CONCERNING MEASURES TO INCREASE ACCESS TO PHARMACY**  
102 **SERVICES.**

---

**Bill Summary**

*(Note: This summary applies to this bill as introduced and does not reflect any amendments that may be subsequently adopted. If this bill passes third reading in the house of introduction, a bill summary that applies to the reengrossed version of this bill will be available at <http://leg.colorado.gov>.)*

Under current law, a pharmacist may receive reimbursement under a health benefit plan and under the medical assistance program (medicaid) for health-care services provided pursuant to a collaborative pharmacy practice agreement. If certain conditions are met, the bill requires health benefit plans that provide hospital, surgical, or medical expense insurance to provide coverage for health-care services provided by a pharmacist that

Shading denotes HOUSE amendment. Double underlining denotes SENATE amendment.  
*Capital letters or bold & italic numbers indicate new material to be added to existing law.*  
*Dashes through the words or numbers indicate deletions from existing law.*

SENATE  
Amended 2nd Reading  
May 5, 2026

HOUSE  
3rd Reading Unamended  
April 21, 2026

HOUSE  
Amended 2nd Reading  
April 20, 2026

are within the pharmacist's scope of practice. Similarly, under medicaid, the bill authorizes reimbursement for services that are within a pharmacist's scope of practice and not duplicative of other pharmacist services or programs reimbursed by medicaid.

Further, solely on the basis of the type of license or certification, a health benefit plan or health insurance carrier shall not discriminate against a pharmacist who is acting within the scope of the pharmacist's license or certification under state law, with respect to participation, referral, reimbursement of covered services, or indemnification, or prohibit a pharmacist from membership in a provider's network.

The bill makes changes to the definitions in the pharmacy practice statutes to include a definition for "final product verification", which is defined as a physical verification process for drug, device, or product orders filled through a pharmacy's electronic system after initial fill by a technician or other automated technology. Final product verification may be delegated by a supervising pharmacist to a certified pharmacy technician or pharmacy intern. The process requires a pharmacy or other outlet to have a continuous quality assessment system in place to periodically verify the accuracy of the final drug, device, or product. A pharmacy intending to implement a final product verification program shall create a plan for final product verification, including how pharmacists' hours will be maintained to provide direct patient care. The state board of pharmacy is required to adopt rules relating to final product verification.

Under current law, a pharmacist has independent prescriptive authority for drugs that are not controlled substances, drug categories, or devices that are prescribed to patients who are at least 12 years old, if certain conditions are met. The bill also adds to the definition of the "practice of pharmacy" to include independent prescriptive authority for drugs that are not controlled substances, drug categories, or devices that are prescribed to patients younger than 12 years old for conditions that do not require a new diagnosis, that are minor and self-limiting, or that have a test that guides diagnosis and are not medications that may only be prescribed pursuant to a certified education program and a limited distribution network.

---

1 *Be it enacted by the General Assembly of the State of Colorado:*

2           **SECTION 1.** In Colorado Revised Statutes, 10-16-144, **amend**  
3 (1) introductory portion, (1)(a), and (2) as follows:

4           **10-16-144. Health-care services provided by pharmacists.**

5           (1) ~~Any~~ A health benefit plan, except supplemental policies

1 covering a specified disease or other limited benefit, that provides  
2 hospital, surgical, or medical expense insurance ~~may~~ MUST provide  
3 coverage for health-care services ~~under a specific treatment protocol~~  
4 provided by a pharmacist if:

5 (a) The pharmacist ~~meets the requirements in part 6 of article 280~~  
6 ~~of title 12~~ IS PROVIDING SERVICES THAT ARE WITHIN THE PHARMACIST'S  
7 SCOPE OF PRACTICE UNDER ARTICLE 280 OF TITLE 12;

8 (2) ~~(a) A health benefit plan described in subsection (1) of this~~  
9 ~~section shall provide coverage for health-care services provided by a~~  
10 ~~pharmacist within a health professional shortage area, as defined in 42~~  
11 ~~U.S.C. sec. 254e, if the conditions specified in subsection (1) of this~~  
12 ~~section are met.~~

13 ~~(b) (a) This subsection (2) does not require a carrier to contract~~  
14 ~~with~~ IF a ~~pharmacy or~~ pharmacist IS willing to abide by the terms and  
15 conditions for participation established by the health benefit plan or  
16 carrier, A HEALTH BENEFIT PLAN OR CARRIER SHALL NOT DISCRIMINATE,  
17 WITH RESPECT TO PARTICIPATION, REFERRAL, OR REIMBURSEMENT OF  
18 COVERED SERVICES OR INDEMNIFICATION AS TO PHARMACISTS WHO ARE  
19 ACTING WITHIN THE SCOPE OF THEIR LICENSE UNDER STATE LAW, SOLELY  
20 ON THE BASIS OF THE TYPE OF LICENSURE. IN SELECTING PROVIDERS OF  
21 HEALTH-CARE SERVICES FOR MEMBERSHIP IN A PROVIDER NETWORK, A  
22 HEALTH BENEFIT PLAN OR CARRIER SHALL NOT DISCRIMINATE AGAINST  
23 PHARMACISTS WHO PROVIDE SERVICES THAT ARE COVERED BY THE PLAN  
24 BY PROHIBITING PHARMACISTS FROM MEMBERSHIP IN A PROVIDER  
25 NETWORK.

26 (b) SUBSECTION (2)(a) OF THIS SECTION SHALL NOT BE CONSTRUED  
27 AS:

1 (I) PROHIBITING A HEALTH BENEFIT PLAN OR CARRIER FROM  
2 INCLUDING PROVIDERS IN A PROVIDER NETWORK ONLY TO THE EXTENT  
3 NECESSARY TO MEET THE NEEDS OF THE HEALTH BENEFIT PLAN AND ITS  
4 ENROLLEES OR FROM LIMITING REFERRALS OR ESTABLISHING ANY OTHER  
5 MEASURE DESIGNED TO MAINTAIN QUALITY AND CONTROL COSTS  
6 CONSISTENT WITH THE PROVISIONS OF THE HEALTH BENEFIT PLAN;

7 (II) REQUIRING A HEALTH BENEFIT PLAN OR CARRIER TO CONTRACT  
8 WITH ANY PROVIDER WILLING TO ABIDE BY THE TERMS AND CONDITIONS  
9 FOR PARTICIPATION ESTABLISHED BY THE HEALTH BENEFIT PLAN OR  
10 CARRIER; OR

11 (III) REQUIRING COVERAGE FOR ANY SERVICE THAT IS NOT  
12 OTHERWISE COVERED UNDER THE TERMS OF A HEALTH BENEFIT PLAN.

13 **SECTION 2.** In Colorado Revised Statutes, 12-280-103, **amend**  
14 (38.5)(a)(X), (38.5)(a)(XI), (39)(g)(IV) introductory portion,  
15 (39)(g)(IV)(C), and (39)(g)(V); and **add** (17.5), (38.5)(a)(XII), and  
16 (39)(g)(VI) as follows:

17 **12-280-103. Definitions - rules.**

18 As used in this article 280, unless the context otherwise requires  
19 or the term is otherwise defined in another part of this article 280:

20 (17.5) "FINAL PRODUCT VERIFICATION" MEANS, AFTER  
21 PRESCRIPTION OR ORDER INFORMATION IS ENTERED INTO A PHARMACY'S  
22 ELECTRONIC SYSTEM AND REVIEWED BY A PHARMACIST FOR ACCURACY,  
23 THERAPEUTIC APPROPRIATENESS, AND OTHER ASPECTS OF DRUG REGIMEN  
24 REVIEW, A PHYSICAL VERIFICATION THAT THE DRUG, DEVICE, OR PRODUCT  
25 SELECTED FROM THE PHARMACY'S INVENTORY IS THE CORRECT DRUG,  
26 DRUG STRENGTH, DRUG FORMULATION, DEVICE, OR PRODUCT FOR THE  
27 PRESCRIPTION OR ORDER.

1 (38.5) (a) "Practice as a pharmacy technician" means engaging in  
2 any of the following activities involved in the practice of pharmacy, under  
3 the supervision and delegation of a supervising pharmacist:

4 (X) Redispensing a prescription drug pursuant to section  
5 12-280-141 (9)(b) and (9)(c); and

6 (XI) Requesting refill authorization from the prescriber or  
7 prescriber's agent and receiving clarifying prescription information from  
8 the prescriber or prescriber's agent; AND

9 (XII) FINAL PRODUCT VERIFICATION FOR A DRUG, DEVICE, OR  
10 PRODUCT THAT IS NOT A CONTROLLED SUBSTANCE.

11 (39) "Practice of pharmacy" means:

12 (g) Exercising independent prescriptive authority:

13 (IV) For drugs that are not controlled substances, drug categories,  
14 or devices that are prescribed in accordance with the product's  
15 FDA-approved labeling and to patients who are at least twelve years of  
16 age OLD and that are limited to conditions that:

17 (C) Have a test that is used to guide diagnosis or clinical  
18 decision-making and is waived under the federal "Clinical Laboratory  
19 Improvement Amendments of 1988", Pub.L. 100-578, as amended, or  
20 AND, IF TESTING OR TREATMENT OCCURS, FOR A PATIENT TWELVE YEARS  
21 OLD OR OLDER BUT UNDER EIGHTEEN YEARS OLD, THE PATIENT'S PRIMARY  
22 CARE PROVIDER IS NOTIFIED AS SOON AS PRACTICABLE CONSISTENT WITH  
23 THE FEDERAL "HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY  
24 ACT OF 1996", PUB.L. 104-191, OR, IF THE PATIENT DOES NOT HAVE OR  
25 DISCLOSE A PRIMARY CARE PROVIDER, THE PATIENT'S PHARMACIST REFERS  
26 THE PATIENT TO A PRIMARY CARE PROVIDER FOR FURTHER CARE;

27 (V) For any FDA-approved product indicated for opioid use

1 disorder in accordance with federal law and regulations, including  
2 medications for opioid use disorder, if authorized pursuant to part 6 of  
3 this article 280; OR

4 (VI) FOR DRUGS THAT ARE NOT CONTROLLED SUBSTANCES, DRUG  
5 CATEGORIES, OR DEVICES THAT ARE PRESCRIBED IN ACCORDANCE WITH  
6 THE PRODUCT'S FDA-APPROVED LABELING AND TO PATIENTS WHO ARE  
7 FIVE YEARS OLD OR OLDER BUT UNDER TWELVE YEARS OLD AND THAT ARE  
8 LIMITED TO CONDITIONS THAT:

9 (A) DO NOT REQUIRE A NEW DIAGNOSIS;

10 (B) ARE MINOR AND GENERALLY SELF-LIMITING; OR

11 (C) HAVE A TEST THAT IS USED TO GUIDE DIAGNOSIS OR CLINICAL  
12 DECISION-MAKING FOR INFLUENZA, SARS-CoV-2, GROUP A  
13 STREPTOCOCCUS, OR RESPIRATORY SYNCYTIAL VIRUS THAT IS WAIVED  
14 UNDER THE FEDERAL "CLINICAL LABORATORY IMPROVEMENT  
15 AMENDMENTS OF 1988", PUB.L. 100-578, AS AMENDED; DO NOT REQUIRE  
16 MEDICATIONS THAT ARE ONLY PRESCRIBED PURSUANT TO A CERTIFIED  
17 EDUCATION PROGRAM AND A LIMITED DISTRIBUTION NETWORK; AND, IF  
18 TESTING OR TREATMENT OCCURS, THE PATIENT'S PRIMARY CARE PROVIDER  
19 IS NOTIFIED AS SOON AS PRACTICABLE CONSISTENT WITH THE FEDERAL  
20 "HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT OF 1996",  
21 PUB.L. 104-191, OR, IF THE PATIENT DOES NOT HAVE OR DISCLOSE A  
22 PRIMARY CARE PROVIDER, THE PATIENT'S PHARMACIST REFERS THE  
23 PATIENT TO A PRIMARY CARE PROVIDER FOR FURTHER CARE;

24 **SECTION 3.** In Colorado Revised Statutes, 12-280-122, **add** (5)  
25 as follows:

26 **12-280-122. Limited authority to delegate activities**  
27 **constituting practice of pharmacy to pharmacy interns or pharmacy**

1 **technicians - supervision ratio - final product verification - rules -**  
2 **definition.**

3 (5) (a) A SUPERVISING PHARMACIST MAY DELEGATE, AND A  
4 PHARMACY TECHNICIAN OR AN INTERN MAY PERFORM UNDER THE  
5 SUPERVISION OF THE SUPERVISING PHARMACIST, TASKS ASSOCIATED WITH  
6 THE PHYSICAL PREPARATION AND PROCESSING OF DRUG, DEVICE, OR  
7 PRODUCT ORDERS THAT ARE NOT FOR CONTROLLED SUBSTANCES.

8 (b) FINAL PRODUCT VERIFICATION TASKS THAT MAY BE  
9 DELEGATED BY THE SUPERVISING PHARMACIST INCLUDE:

10 (I) VERIFICATION OF THE PRESCRIPTION OR DRUG, DEVICE, OR  
11 PRODUCT BY A SECOND PHARMACY TECHNICIAN OR INTERN CONCERNING  
12 THE WORK OF THE FIRST PHARMACY TECHNICIAN OR INTERN;

13 (II) USE OF BARCODE OR OTHER TECHNOLOGY TO VERIFY EACH  
14 DRUG, DEVICE, OR PRODUCT PRIOR TO ADMINISTRATION TO AN INDIVIDUAL  
15 BY A HEALTH-CARE PROVIDER;

16 (III) VERIFICATION BY A SECOND PHARMACY TECHNICIAN OR  
17 INTERN CONCERNING THE WORK OF THE FIRST PHARMACY TECHNICIAN OR  
18 INTERN IN THE REPACKAGING OF DRUGS FROM BULK TO UNIT DOSE; OR

19 (IV) OTHER ACTIVITIES AS AUTHORIZED BY THE BOARD BY RULE.

20 (c) IN DELEGATING FINAL PRODUCT VERIFICATION TASKS, A  
21 SUPERVISING PHARMACIST SHALL USE THE PHARMACIST'S REASONABLE  
22 PROFESSIONAL JUDGMENT AND SHALL ENSURE THAT AUTHORIZED TASKS  
23 DO NOT REQUIRE THE EXERCISE OF DISCRETION OR CLINICAL JUDGMENT BY  
24 A PHARMACY TECHNICIAN.

25 (d) A PHARMACY OR OTHER OUTLET SHALL HAVE A CONTINUOUS  
26 QUALITY ASSESSMENT SYSTEM IN PLACE TO PERIODICALLY VERIFY THE  
27 ACCURACY OF A FINAL DRUG, DEVICE, OR PRODUCT, WHICH INCLUDES A

1 PROCESS FOR THE RECORDING AND EVALUATION OF ERRORS THAT OCCUR  
2 AND POTENTIAL ERRORS, EVEN IF THE ERRORS DO NOT REACH THE  
3 PATIENT.

4 (e) A PHARMACY INTENDING TO IMPLEMENT A FINAL PRODUCT  
5 VERIFICATION PROGRAM SHALL CREATE AND MAINTAIN A PROGRAM PLAN,  
6 INCLUDING HOW PHARMACISTS' HOURS WILL BE MAINTAINED AND  
7 REDIRECTED FOR PROVIDING DIRECT PATIENT CARE ACTIVITIES.

8 (f) NOLATER THAN DECEMBER 31, 2026, THE BOARD SHALL ADOPT  
9 RULES CONCERNING FINAL PRODUCT VERIFICATION BY A PHARMACY  
10 TECHNICIAN OR INTERN PURSUANT TO THIS SUBSECTION (5). THE BOARD'S  
11 RULES MUST INCLUDE:

12 (I) TRAINING REQUIREMENTS;

13 (II) EXCLUDED MEDICATIONS;

14 (III) LIABILITY ISSUES; AND

15 (IV) ANY OTHER RULES THE BOARD DEEMS APPROPRIATE.

16 **SECTION 4.** In Colorado Revised Statutes, 25.5-5-511, **amend**  
17 (2)(a) as follows:

18 **25.5-5-511. Reimbursement for pharmacists' services -**  
19 **legislative declaration.**

20 (2) (a) A pharmacist is eligible to receive reimbursement under the  
21 medical assistance program for medically necessary services ~~authorized~~  
22 ~~in part 6 of~~ THAT ARE WITHIN THE PHARMACIST'S SCOPE OF PRACTICE  
23 PURSUANT TO article 280 of title 12 AND that are not duplicative of other  
24 pharmacist services or programs reimbursed under the medical assistance  
25 program.

26 **SECTION 5. Act subject to petition - effective date.** This act  
27 takes effect at 12:01 a.m. on the day following the expiration of the

1 ninety-day period after final adjournment of the general assembly (August  
2 12, 2026, if adjournment sine die is on May 13, 2026); except that, if a  
3 referendum petition is filed pursuant to section 1 (3) of article V of the  
4 state constitution against this act or an item, section, or part of this act  
5 within such period, then the act, item, section, or part will not take effect  
6 unless approved by the people at the general election to be held in  
7 November 2026 and, in such case, will take effect on the date of the  
8 official declaration of the vote thereon by the governor.